Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells

BMC Pharmacology

Volumn 9, Issue , 2009, Pages 10-

  Vik Mo, Audun O ^a,b   Fernø, Johan ^a,b   Skrede, Silje ^a,b   Steen, Vidar M ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN E; CLOZAPINE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMIPRAMINE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MEMBRANE PROTEIN; NIEMANN PICK TYPE C1 LIKE 1 PROTEIN; NIEMANN PICK TYPE C1 PROTEIN; NIEMANN PICK TYPE C2 PROTEIN; OLANZAPINE; PSYCHOTROPIC AGENT; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; APOLIPOPROTEIN E2; CHOLESTEROL;

ARTICLE; ASTROCYTOMA CELL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GENE EXPRESSION; GLIOMA CELL; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID TRANSPORT; LIPOGENESIS; METABOLIC DISORDER; MYELINATION; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; SYNAPTOGENESIS; TRANSCRIPTION INITIATION; UPREGULATION; ANALYSIS OF VARIANCE; BRAIN; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENETICS; LIVER; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; APOLIPOPROTEIN E2; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; BRAIN; CELL LINE, TUMOR; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIVER; PSYCHOTROPIC DRUGS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROL REGULATORY ELEMENT BINDING PROTEINS; TIME FACTORS; UP-REGULATION;

EID: 70350719357     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-9-10     Document Type: Article

References (40)

1. Raeder MB, Ferno J, Vik-Mo AO, Steen VM. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?. Mol Cell Biochem 2006, 289(1-2):167-173. 10.1007/s11010-006-9160-4, 16718372.
2. Ferno J, Skrede S, Vik-Mo AO, Havik B, Steen VM. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006, 7:69. 10.1186/1471-2202-7-69, 1635424, 17052361.
3. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J 2005, 5(5):298-304. 10.1038/sj.tpj.6500323, 16027736.
4. Raeder MB, Ferno J, Glambek M, Stansberg C, Steen VM. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett 2006, 395(3):185-190. 10.1016/j.neulet.2005.10.096, 16324787.
5. Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004, 45(8):1375-1397. 10.1194/jlr.R400004-JLR200, 15254070.
6. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294(5545):1354-1357. 10.1126/science.294.5545.1354, 11701931.
7. Thomas EA, Dean B, Pavey G, Sutcliffe JG. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc Natl Acad Sci USA 2001, 98(7):4066-4071. 10.1073/pnas.071056198, 31180, 11274430.
8. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001, 98(8):4746-4751. 10.1073/pnas.081071198, 31905, 11296301.
9. Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int J Neuropsychopharmacol 2008, 11(1):49-61. 10.1017/S1461145707007730, 17708778.
10. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362(9386):798-805. 10.1016/S0140-6736(03)14289-4, 13678875.
11. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 2005, 80(1):55-59. 10.1016/j.schres.2005.05.001, 15964176.
12. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32(4):765-772. 10.1038/sj.npp.1301142, 16823387.
13. Yang LH, Chen TM, Yu ST, Chen YH. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 2007, 56(3):202-208. 10.1016/j.phrs.2007.05.007, 17651982.
14. Minet-Ringuet J, Even PC, Valet P, Carpene C, Visentin V, Prevot D, Daviaud D, Quignard-Boulange A, Tome D, de Beaurepaire R. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 2007, 12(6):562-571. 10.1038/sj.mp.4001948, 17211438.
15. Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 2008, 11(5):679-84. Epub 2008 Feb 1, 10.1017/S1461145708008468, 18241359.
16. Adams CM, Goldstein JL, Brown MS. Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci USA 2003, 100(19):10647-10652. 10.1073/pnas.1534833100, 196858, 12963821.
17. Ulven SM, Dalen KT, Gustafsson JA, Nebb HI. LXR is crucial in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 2005, 73(1):59-63. 10.1016/j.plefa.2005.04.009, 15913974.
18. Vance JE, Karten B, Hayashi H. Lipid dynamics in neurons. Biochem Soc Trans 2006, 34(Pt 3):399-403.
19. Repa JJ, Mangelsdorf DJ. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 2002, 8(11):1243-1248. 10.1038/nm1102-1243, 12411951.
20. Dean B, Laws SM, Hone E, Taddei K, Scarr E, Thomas EA, Harper C, McClean C, Masters C, Lautenschlager N. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry 2003, 54(6):616-622. 10.1016/S0006-3223(03)00075-1, 13129656.
21. Digney A, Keriakous D, Scarr E, Thomas E, Dean B. Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry 2005, 57(7):711-715. 10.1016/j.biopsych.2004.12.028, 15820227.
22. Dean B, Digney A, Sundram S, Thomas E, Scarr E. Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res 2008, 158(1):75-78.
23. Davis KL, Haroutunian V. Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362(9386):758. 10.1016/S0140-6736(03)14297-3, 13678867.
24. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6(3):219-233. 10.2174/187152707780619326, 17511618.
25. Goritz C, Mauch DH, Nagler K, Pfrieger FW. Role of glia-derived cholesterol in synaptogenesis: new revelations in the synapse-glia affair. J Physiol Paris 2002, 96(3-4):257-263. 10.1016/S0928-4257(02)00014-1, 12445904.
26. Le Hellard S, Mühleisen TW, Djurovic S, Ferno J, Ouriaghi Z, Mattheisen M, Vasilescu C, Raeder MB, Hansen T, Strohmaier J. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcriptions factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol Psychiatry 2008, doi:101038/mp2008110.
27. Boadu E, Francis GA. The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways. J Mol Med 2006, 84(4):266-275. 10.1007/s00109-005-0001-9, 16328207.
28. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, Nagao T, Nishimaki-Mogami T. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 2007, 282(29):21090-21099. 10.1074/jbc.M701228200, 17526932.
29. Zeng L, Liao H, Liu Y, Lee TS, Zhu M, Wang X, Stemerman MB, Zhu Y, Shyy JY. Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells: a novel role of SREBP in regulating cholesterol metabolism. J Biol Chem 2004, 279(47):48801-48807. 10.1074/jbc.M407817200, 15358760.
30. Engelking LJ, Kuriyama H, Hammer RE, Horton JD, Brown MS, Goldstein JL, Liang G. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest 2004, 113(8):1168-1175. 385408, 15085196.
31. Repa JJ, Li H, Frank-Cannon TC, Valasek MA, Turley SD, Tansey MG, Dietschy JM. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 2007, 27(52):14470-14480. 10.1523/JNEUROSCI.4823-07.2007, 18160655.
32. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, Li X, Dyck LE, Devon RM, Deng Y. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008, 13(7):697-708. 10.1038/sj.mp.4002064, 17684494.
33. Chen F, Madsen TM, Wegener G, Nyengaard JR. Changes in rat hippocampal CA1 synapses following imipramine treatment. Hippocampus 2008, 18(7):631-9. 10.1002/hipo.20423, 18306301.
34. Bartzokis G, Lu PH, Nuechterlein KH, Gitlin M, Doi C, Edwards N, Lieu C, Altshuler LL, Mintz J. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr Res 2007, 93(1-3):13-22. 10.1016/j.schres.2007.02.011, 1974878, 17407804.
35. ADA, Association AP, Endocrinologists AAoC, Obesity NAAftSo Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27(2):596-601. 10.2337/diacare.27.2.596, 14747245.
36. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS spectrums 2006, 11(7 Suppl 7):32-39.
37. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Ferno J, Gebhardt S, Hinney A, Remschmidt H, Krieg JC, Mehler-Wex C. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. Mol Psychiatry 2008,
38. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303(5661):1201-1204. 10.1126/science.1093131, 14976318.
39. Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006, 163(7):1276-1279. 10.1176/appi.ajp.163.7.1276, 16816235.
40. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet E, Stip E, Williams R, Macewan GW, Birmingham CL. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007, 32(5):331-338. 1963353, 17823649.